Draft Report of the Threshold Working Group, Center for Food Safety and Applied Nutrition: Approaches to Establish Thresholds for Major Food Allergens and for Gluten in Food; Availability; Request for Comments and for Scientific Data and Information, 35257-35259 [05-12041]
Download as PDF
35257
Federal Register / Vol. 70, No. 116 / Friday, June 17, 2005 / Notices
relating health care choices with
individual beliefs may help guide these
educational efforts. The intent of this
survey is to understand the role
personal responsibility plays when
people with Medicare make health care
decisions; Affected Public: Individuals
or Households; Number of Respondents:
1580; Total Annual Responses: 1580;
Total Annual Hours: 300.
To obtain copies of the supporting
statement and any related forms for the
proposed paperwork collections
referenced above, access CMS’ Web site
address at https://www.cms.hhs.gov/
regulations/pra/, or e-mail your request,
including your address, phone number,
OMB number, and CMS document
identifier, to Paperwork@cms.hhs.gov,
or call the Reports Clearance Office on
(410) 786–1326.
Written comments and
recommendations for the proposed
information collections must be mailed
within 60 days of this notice to the
address below: CMS, Office of Strategic
Operations and Regulatory Affairs,
Division of Regulations Development,
Attention: Melissa Musotto, PRA
Analyst, Room C4–26–05, 7500 Security
Boulevard, Baltimore, Maryland 21244–
1850.
Dated: June 10, 2005.
Jimmy Wickliffe,
Reports Clearance Officer, Office of Strategic
Operations and Regulatory Affairs.
[FR Doc. 05–11931 Filed 6–16–05; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Children and
Families
Submission for OMB Review;
Comment Request
Title: Follow-up to the National
Survey of Child and Adolescent WellBeing.
OMB No.: 0970–0202.
Description: The Department of
Health and Human Services intends to
collect data on a subset of children and
families who have participated in the
National Survey of Child and
Adolescent Well-Being (NSCAW). The
NSCAW was authorized under Section
429 of the Personal Responsibility and
Work Opportunity Reconciliation Act of
1996. The survey began in November
1999 with a national sample of 5,501
children ages 0–14 who had been the
subject of investigation by Child
Protective Services (CPS) during the
baseline data collection period, which
extended from November 1999 through
April 2000. Direct assessments and
interviews were conducted with the
children themselves, their primary
caregivers, their caseworkers, and, for
school-aged children, their teachers.
Follow-up data collections were
conducted 12 months, 18 months and
36 months post-baseline. The current
data collection plan involves only a
subset of 1,497 children from the
original sample, that is, children who
were ages 0–12 months during the
baseline period. The original sample
design for NSCAW was stratified to
include an over-sample of infants; thus,
the subset that is the subject of this data
collection is a representative sample of
infants who were the targets of CPS
investigations during the survey’s
baseline data collection period. This
group will be at the beginning of their
formal schooling as the next data
collection begins, and will allow for the
identification of early risk and
protective factors, as well as the
influence of services and service
systems, on their functioning as they
enter this critical transition period.
The NSCAW is unique in that it is the
only source of nationally representative,
firsthand information about the
functioning and well-being, service
needs and service utilization of children
and families who come to the attention
of the child welfare system. Information
is collected about children’s cognitive,
social, emotional, behavioral and
adaptive functioning, as well as family
and community factors that are likely to
influence their functioning. Family
service needs and service utilization
also are addressed in the data collection.
The data collection for the follow-up
will follow the same format as that used
in previous rounds of data collection,
and will employ the same instruments
that have been used with 5- to 7-yearolds in previous rounds. Data from
NSCAW are made available to the
research community through licensing
arrangements from the National Data
Archive on Child Abuse and Neglect,
housed at Cornell University.
Respondents: Children, who are
clients of the child welfare system, their
primary caregivers, caseworkers, and
teachers.
ANNUAL BURDEN ESTIMATES
Number of respondents
Instrument
Number of responses per
respondent
Average burden hours per
response
1,017
1,017
299
790
299
1
1
1
1
1
1.10
1.40
.75
.75
1.25
Child Interview .................................................................................................
Caregiver Interview ..........................................................................................
Caseworker Interview ......................................................................................
Teacher Questionnaire ....................................................................................
Salivary cortisol collection ................................................................................
Estimated Total Annual Burden
Hours: 3,733.
Additional Information: Copies of the
proposed collection may be obtained by
writing to the Administration for
Children and Families, Office of
Administration, Office of Information
Services, 370 L’Enfant Promnade, SW.,
Washington, DC 20447, Attn: ACF
Reports Clearance Officer. All requests
should be identified by the title of the
VerDate jul<14>2003
17:59 Jun 16, 2005
Jkt 205001
information collection. E-mail address:
grjohnson@acf.hhs.gov.
OMB Comment: OMB is required to
make a decision concerning the
collection of information between 30
and 60 days after publication of this
document in the Federal Register.
Therefore, a comment is best assured of
having its full effect if OMB receives it
within 30 days of publication. Written
comments and recommendations for the
proposed information collection should
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
Total burden
hours
1,119
1,424
224
592
374
be sent directly to the following: Office
of Management and Budget, Paperwork
Reduction Project, Attn: Desk Officer for
ACF, E-mail address: Katherine_T._
Astrich@omb.eo.gov.
Dated: June 13, 2005.
Robert Sargis,
Reports Clearance Officer.
[FR Doc. 05–11969 Filed 6–16–05; 8:45 am]
BILLING CODE 4184–01–M
E:\FR\FM\17JNN1.SGM
17JNN1
35258
Federal Register / Vol. 70, No. 116 / Friday, June 17, 2005 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2005N–0231]
Draft Report of the Threshold Working
Group, Center for Food Safety and
Applied Nutrition: Approaches to
Establish Thresholds for Major Food
Allergens and for Gluten in Food;
Availability; Request for Comments
and for Scientific Data and Information
AGENCY:
Food and Drug Administration,
HHS.
Notice; request for comments
and for scientific data and information.
ACTION:
SUMMARY: The Food and Drug
Administration (FDA) is announcing the
availability of a draft report entitled
‘‘Approaches to Establish Thresholds for
Major Food Allergens and for Gluten in
Food.’’ The draft report was prepared by
an interdisciplinary group of scientists
from FDA’s Center for Food Safety and
Applied Nutrition (CFSAN). This report
was prepared to facilitate the further
development of CFSAN’s policy for food
allergens, including the center’s
implementation of the Food Allergen
Labeling and Consumer Protection Act
of 2004 (FALCPA).
DATES: Submit comments and scientific
data and information by August 16,
2005.
ADDRESSES: Submit written comments
and scientific data and information to
the Division of Dockets Management
(HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. Submit
electronic comments and scientific data
and information to https://www.fda.gov/
dockets/ecomments.
Submit written requests for single
copies of the draft report to Sherri
Dennis, Center for Food Safety and
Applied Nutrition (see FOR FURTHER
INFORMATION CONTACT). Send one selfadhesive label with your address to
assist that office in processing your
request. You also may request a copy of
the draft report by faxing your name and
mailing address with the name of the
document you are requesting to the
CFSAN Outreach and Information
Center at 1–877–366–3322. See the
SUPPLEMENTARY INFORMATION section for
electronic access to this document.
FOR FURTHER INFORMATION CONTACT:
Sherri B. Dennis, Center for Food Safety
and Applied Nutrition (HFS–06), Food
and Drug Administration, 5100 Paint
Branch Pkwy., College Park, MD 20740,
301–436–1903.
SUPPLEMENTARY INFORMATION:
VerDate jul<14>2003
17:59 Jun 16, 2005
Jkt 205001
I. Background
Food allergies are estimated to affect
approximately six percent of infants and
children and four percent of adults in
the United States. A food allergy is an
idiosyncratic response of the immune
system to naturally occurring proteins
in a food. The most severe and
immediately life-threatening food
allergic responses are associated with
immunoglobulin E (IgE) mediated
hypersensitivity. In this country, eight
foods or food groups—peanuts,
soybeans, cow’s milk, eggs, fish,
crustacean shellfish, tree nuts, and
wheat—account for 90 percent of food
allergies.
Food allergic reactions vary in
severity, ranging from mild symptoms
(such as skin or eye irritation) to severe,
life-threatening responses (such as
anaphylaxis or systemic shock.) The
amount of protein needed to provoke an
allergic response varies. Factors that
affect the severity of an allergic response
include the food from which the protein
is derived, the nature of the processing
of the food, the food matrix containing
the allergenic protein, and the
sensitivity of the individual. There is a
general consensus that, for most food
allergic individuals, exposure to protein
below a certain level is unlikely to elicit
an allergic response. Although it has not
been clearly defined, the term
‘‘threshold’’ has frequently been used to
describe the lowest level of protein from
an allergenic food that will elicit a
response in a sensitive individual.
There is currently no known cure for
food allergies. Accordingly, strict
avoidance of the offending food or foods
at levels that will elicit an adverse effect
is the only means to prevent potentially
serious reactions. Thus, food allergic
consumers need accurate, complete, and
informative labels on food to protect
themselves.
In August 2004, Congress enacted the
FALCPA (Public Law 108–282), which
amends the Federal Food, Drug, and
Cosmetic Act (the act), and requires that
the label of a food product that is or
contains an ingredient that bears or
contains a ‘‘major food allergen’’ declare
the presence of the allergen as specified
by FALCPA. FALCPA defines ‘‘major
food allergen’’ as one of eight foods or
a food ingredient that contains protein
derived from one of those foods.
FALCPA provides two processes by
which an ingredient may be exempted
from the FALCPA labeling
requirements—a petition process
(section 403 of the act (21 U.S.C.
343(w)(6)) and a notification process (21
U.S.C. 343(w)(7)). Under the petition
process, an ingredient may be exempt if
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
the petitioner demonstrates that the
ingredient ‘‘does not cause an allergic
reaction that poses a risk to human
health.’’ Under the notification process,
an ingredient may be exempt if the
notification contains scientific evidence
that demonstrates that the ingredient
‘‘does not contain allergenic protein,’’ or
if FDA previously has determined,
under section 409 of the act (21 U.S.C.
348), that the food ingredient does not
cause an allergic response that poses a
risk to human health. Understanding
food allergen thresholds and developing
a sound analytical framework for such
thresholds are likely to be centrally
important to FDA’s analysis of, and
response to, FALCPA petitions and
notifications.
FALCPA also requires FDA to define
and permit the use of the term ‘‘gluten
free.’’ Such labeling is important to
patients suffering from celiac disease, an
immune-mediated illness. Strict
avoidance of gluten at levels that will
elicit an adverse effect is the only means
to prevent potentially serious reactions.
Thus, consumers susceptible to celiac
disease need accurate, complete, and
informative labels on food to protect
themselves. Understanding thresholds
for gluten will help FDA develop a
definition of ‘‘gluten free’’ and identify
appropriate use of the term.
Section 204 of FALCPA directs FDA
to prepare and submit a report to
Congress. The report will focus
principally on the issue of cross-contact
of foods with food allergens, and will
describe the types, current use of, and
consumer preferences with respect to
advisory labeling. Cross-contact may
occur as part of the food production
process where residues of an allergenic
food are present in the manufacturing
environment and are unintentionally
incorporated into a food that is not
intended to contain the food allergen,
and thus, the allergen is not declared as
an ingredient on the food’s label. In
some cases, the possible presence of the
food allergen is declared by a voluntary
advisory statement. Understanding food
allergen thresholds and developing a
sound analytical framework for such
thresholds is also likely to be useful in
addressing food allergen cross-contact
and the use of advisory labeling.
Both as part of its ongoing risk
management of food allergens and in
response to FALCPA, CFSAN
established an internal,
interdisciplinary group (the Threshold
Working Group). The Threshold
Working Group was established to
evaluate the current state of scientific
knowledge regarding food allergies and
celiac disease, to consider various
approaches to establishing thresholds
E:\FR\FM\17JNN1.SGM
17JNN1
Federal Register / Vol. 70, No. 116 / Friday, June 17, 2005 / Notices
for food allergens and for gluten, and to
identify the biological concepts and data
needed to evaluate the scientific
soundness of each approach. The draft
report entitled ‘‘Approaches to Establish
Thresholds for Major Food Allergens
and for Gluten in Food’’ is the result of
the working group’s deliberations.
In the Federal Register of May 23,
2005 (70 FR 29528), FDA announced a
meeting of the agency’s Food Advisory
Committee (FAC) on July 13, 14, and 15,
2005. At this meeting, the FAC will be
asked to evaluate the draft report
entitled ‘‘Approaches to Establish
Thresholds for Major Food Allergens
and for Gluten in Food.’’ In particular,
the FAC will advise FDA whether, in
the committee’s view, the draft report is
scientifically sound in its analyses and
approaches and adequately considers
available relevant data on food allergens
and on gluten. In seeking the
committee’s advice, FDA plans to pose
a series of scientific questions. These
questions will be posted on CFSAN’s
Web site at https://www.cfsan.fda.gov/
~lrd/vidtel.html on July 12, 2005.
Members of the public who may wish to
participate in the FAC meeting, by
written submission or an oral
presentation, should consult the
meeting notice for information regarding
such participation.
In addition to the FAC proceedings,
the agency believes it would be useful
to receive public comments on the
Threshold Working Group’s draft report.
The draft report describes a number of
areas in which the working group
concluded that the body of scientific
data relating to food allergen thresholds
is incomplete. Accordingly, FDA
requests that members of the public
submit comments and any relevant
scientific data and information,
particularly data and information that
can fill the data gaps identified in the
draft report.
II. Request for Comments and for
Scientific Data and Information
Interested persons should submit
comments and scientific data and
information to the Division of Dockets
Management (see ADDRESSES). Three
copies of all comments and scientific
data and information are to be
submitted. Individuals submitting
written information or anyone
submitting electronic comments may
submit one copy. Submissions are to be
identified with the docket number
found in brackets in the heading of this
document and may be accompanied by
supporting information. Received
submissions may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday.
VerDate jul<14>2003
17:59 Jun 16, 2005
Jkt 205001
Information submitted after the closing
date will not be considered except by
petition under 21 CFR 10.30.
III. Electronic Access
The draft report is available
electronically at https://
www.cfsan.fda.gov/~dms/whalrgy.html.
Dated: June 14, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 05–12041 Filed 6–15–05; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Empahsis Panel; Emerging
Technologies for Cancer Research.
Date: July 14–15, 2005.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Contact Person: Joyce C. Pegues, PhD;
Scientific Review Administrator; Special
Review Administrator; Special Review and
Logistics Branch; Division of Extramural
Activities; National Cancer Institute; 6116
Executive Blvd. 7149; Bethesda, MD 20892.
301/594–1286. peguesj@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
35259
Dated: June 10, 2005.
LaVerne Y. Springfield,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–11987 Filed 6–16–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung and Blood
Institute; Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel
Review of Training Applications (T32s).
Date: July 11, 2005.
Time: 8:30 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Sheraton Columbia Hotel, 10207
Wincopin Circle, Columbia, MD 21004.
Contact Person: Charles Joyce, PhD,
Review Branch, NHLBI, National Institutes of
Health, 6701 Rockledge Drive, Room 7196,
Bethesda, MD 20892, (301) 435–0288.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel,
Myelodysplastic Syndrome (MDS): Seeking
cure through discovery on pathogenesis and
disease progression.
Date: July 12–13, 2005.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Sheraton Columbia Hotel, 10207
Wincopin Circle, Columbia, MD 21004.
Contact Person: Katherine M. Malinda,
PhD, Scientific Review Administrator,
Review Branch, Division of Extramural
Affairs, National Heart, Lung, and Blood
Institute, National Institutes of Health, 6701
Rockledge Drive, Room 7198, Bethesda, MD
20892, (301) 435–0297
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel
Cellular and Genetic Discovery Toward
Curative Therapy in Myeloproliferative
Disorders (MPD)
Date: July 13, 2005.
Time: 8 a.m. to 5 p.m.
E:\FR\FM\17JNN1.SGM
17JNN1
Agencies
[Federal Register Volume 70, Number 116 (Friday, June 17, 2005)]
[Notices]
[Pages 35257-35259]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-12041]
[[Page 35258]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 2005N-0231]
Draft Report of the Threshold Working Group, Center for Food
Safety and Applied Nutrition: Approaches to Establish Thresholds for
Major Food Allergens and for Gluten in Food; Availability; Request for
Comments and for Scientific Data and Information
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice; request for comments and for scientific data and
information.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
availability of a draft report entitled ``Approaches to Establish
Thresholds for Major Food Allergens and for Gluten in Food.'' The draft
report was prepared by an interdisciplinary group of scientists from
FDA's Center for Food Safety and Applied Nutrition (CFSAN). This report
was prepared to facilitate the further development of CFSAN's policy
for food allergens, including the center's implementation of the Food
Allergen Labeling and Consumer Protection Act of 2004 (FALCPA).
DATES: Submit comments and scientific data and information by August
16, 2005.
ADDRESSES: Submit written comments and scientific data and information
to the Division of Dockets Management (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.
Submit electronic comments and scientific data and information to
https://www.fda.gov/dockets/ecomments.
Submit written requests for single copies of the draft report to
Sherri Dennis, Center for Food Safety and Applied Nutrition (see FOR
FURTHER INFORMATION CONTACT). Send one self-adhesive label with your
address to assist that office in processing your request. You also may
request a copy of the draft report by faxing your name and mailing
address with the name of the document you are requesting to the CFSAN
Outreach and Information Center at 1-877-366-3322. See the
SUPPLEMENTARY INFORMATION section for electronic access to this
document.
FOR FURTHER INFORMATION CONTACT: Sherri B. Dennis, Center for Food
Safety and Applied Nutrition (HFS-06), Food and Drug Administration,
5100 Paint Branch Pkwy., College Park, MD 20740, 301-436-1903.
SUPPLEMENTARY INFORMATION:
I. Background
Food allergies are estimated to affect approximately six percent of
infants and children and four percent of adults in the United States. A
food allergy is an idiosyncratic response of the immune system to
naturally occurring proteins in a food. The most severe and immediately
life-threatening food allergic responses are associated with
immunoglobulin E (IgE) mediated hypersensitivity. In this country,
eight foods or food groups--peanuts, soybeans, cow's milk, eggs, fish,
crustacean shellfish, tree nuts, and wheat--account for 90 percent of
food allergies.
Food allergic reactions vary in severity, ranging from mild
symptoms (such as skin or eye irritation) to severe, life-threatening
responses (such as anaphylaxis or systemic shock.) The amount of
protein needed to provoke an allergic response varies. Factors that
affect the severity of an allergic response include the food from which
the protein is derived, the nature of the processing of the food, the
food matrix containing the allergenic protein, and the sensitivity of
the individual. There is a general consensus that, for most food
allergic individuals, exposure to protein below a certain level is
unlikely to elicit an allergic response. Although it has not been
clearly defined, the term ``threshold'' has frequently been used to
describe the lowest level of protein from an allergenic food that will
elicit a response in a sensitive individual.
There is currently no known cure for food allergies. Accordingly,
strict avoidance of the offending food or foods at levels that will
elicit an adverse effect is the only means to prevent potentially
serious reactions. Thus, food allergic consumers need accurate,
complete, and informative labels on food to protect themselves.
In August 2004, Congress enacted the FALCPA (Public Law 108-282),
which amends the Federal Food, Drug, and Cosmetic Act (the act), and
requires that the label of a food product that is or contains an
ingredient that bears or contains a ``major food allergen'' declare the
presence of the allergen as specified by FALCPA. FALCPA defines ``major
food allergen'' as one of eight foods or a food ingredient that
contains protein derived from one of those foods. FALCPA provides two
processes by which an ingredient may be exempted from the FALCPA
labeling requirements--a petition process (section 403 of the act (21
U.S.C. 343(w)(6)) and a notification process (21 U.S.C. 343(w)(7)).
Under the petition process, an ingredient may be exempt if the
petitioner demonstrates that the ingredient ``does not cause an
allergic reaction that poses a risk to human health.'' Under the
notification process, an ingredient may be exempt if the notification
contains scientific evidence that demonstrates that the ingredient
``does not contain allergenic protein,'' or if FDA previously has
determined, under section 409 of the act (21 U.S.C. 348), that the food
ingredient does not cause an allergic response that poses a risk to
human health. Understanding food allergen thresholds and developing a
sound analytical framework for such thresholds are likely to be
centrally important to FDA's analysis of, and response to, FALCPA
petitions and notifications.
FALCPA also requires FDA to define and permit the use of the term
``gluten free.'' Such labeling is important to patients suffering from
celiac disease, an immune-mediated illness. Strict avoidance of gluten
at levels that will elicit an adverse effect is the only means to
prevent potentially serious reactions. Thus, consumers susceptible to
celiac disease need accurate, complete, and informative labels on food
to protect themselves. Understanding thresholds for gluten will help
FDA develop a definition of ``gluten free'' and identify appropriate
use of the term.
Section 204 of FALCPA directs FDA to prepare and submit a report to
Congress. The report will focus principally on the issue of cross-
contact of foods with food allergens, and will describe the types,
current use of, and consumer preferences with respect to advisory
labeling. Cross-contact may occur as part of the food production
process where residues of an allergenic food are present in the
manufacturing environment and are unintentionally incorporated into a
food that is not intended to contain the food allergen, and thus, the
allergen is not declared as an ingredient on the food's label. In some
cases, the possible presence of the food allergen is declared by a
voluntary advisory statement. Understanding food allergen thresholds
and developing a sound analytical framework for such thresholds is also
likely to be useful in addressing food allergen cross-contact and the
use of advisory labeling.
Both as part of its ongoing risk management of food allergens and
in response to FALCPA, CFSAN established an internal, interdisciplinary
group (the Threshold Working Group). The Threshold Working Group was
established to evaluate the current state of scientific knowledge
regarding food allergies and celiac disease, to consider various
approaches to establishing thresholds
[[Page 35259]]
for food allergens and for gluten, and to identify the biological
concepts and data needed to evaluate the scientific soundness of each
approach. The draft report entitled ``Approaches to Establish
Thresholds for Major Food Allergens and for Gluten in Food'' is the
result of the working group's deliberations.
In the Federal Register of May 23, 2005 (70 FR 29528), FDA
announced a meeting of the agency's Food Advisory Committee (FAC) on
July 13, 14, and 15, 2005. At this meeting, the FAC will be asked to
evaluate the draft report entitled ``Approaches to Establish Thresholds
for Major Food Allergens and for Gluten in Food.'' In particular, the
FAC will advise FDA whether, in the committee's view, the draft report
is scientifically sound in its analyses and approaches and adequately
considers available relevant data on food allergens and on gluten. In
seeking the committee's advice, FDA plans to pose a series of
scientific questions. These questions will be posted on CFSAN's Web
site at https://www.cfsan.fda.gov/lrd/vidtel.html on July 12, 2005.
Members of the public who may wish to participate in the FAC meeting,
by written submission or an oral presentation, should consult the
meeting notice for information regarding such participation.
In addition to the FAC proceedings, the agency believes it would be
useful to receive public comments on the Threshold Working Group's
draft report. The draft report describes a number of areas in which the
working group concluded that the body of scientific data relating to
food allergen thresholds is incomplete. Accordingly, FDA requests that
members of the public submit comments and any relevant scientific data
and information, particularly data and information that can fill the
data gaps identified in the draft report.
II. Request for Comments and for Scientific Data and Information
Interested persons should submit comments and scientific data and
information to the Division of Dockets Management (see ADDRESSES).
Three copies of all comments and scientific data and information are to
be submitted. Individuals submitting written information or anyone
submitting electronic comments may submit one copy. Submissions are to
be identified with the docket number found in brackets in the heading
of this document and may be accompanied by supporting information.
Received submissions may be seen in the Division of Dockets Management
between 9 a.m. and 4 p.m., Monday through Friday. Information submitted
after the closing date will not be considered except by petition under
21 CFR 10.30.
III. Electronic Access
The draft report is available electronically at https://
www.cfsan.fda.gov/dms/wh-alrgy.html.
Dated: June 14, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 05-12041 Filed 6-15-05; 8:45 am]
BILLING CODE 4160-01-S